Is Retatrutide the Same as Ozempic?

By Peptide News Forum, September 23rd, 2026

No, retatrutide targets 3 hormones (GLP-1, GIP, glucagon); Ozempic targets only GLP-1.

Retatrutide  and Ozempic are not the same drug, and the differences go well beyond the name. This is one of the most common points of confusion in the current wave of GLP-1 drug coverage, so it’s worth breaking down clearly: different manufacturers, different mechanisms, and critically, very different regulatory status. This blog covers why Retatrutide vs Ozempic is an unequal comparison.

Key Takeaways

• Retatrutide and Ozempic are different drugs from different companies, not variations of the same medication.
• Ozempic (semaglutide) targets one hormone receptor (GLP-1) and has been FDA-approved since 2017.
• Retatrutide targets three receptors (GLP-1, GIP, and glucagon) and remains investigational, with an FDA submission planned for early 2027.
• Retatrutide has shown some of the largest weight-loss results reported in this drug class so far, but that data comes from trials, not real-world approved use.
• Counterfeit retatrutide is already being sold online despite the drug not being approved; the FDA has specifically warned against this.
• If you’re currently seeking weight loss or diabetes treatment, only FDA-approved options like Ozempic, Wegovy, Mounjaro, or Zepbound are actually available by prescription today.

Ozempic is semaglutide, an FDA-approved GLP-1 drug from Novo Nordisk, on the market since 2017. Retatrutide is a completely different, investigational drug from Eli Lilly that targets three hormone receptors instead of one and has not been FDA approved for any use. Both are injectable, weekly, peptide-based drugs discussed in similar news coverage, which is likely why they get confused, but they are not interchangeable in any sense.

What Is Ozempic?

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It was first approved by the FDA in 2017 for type 2 diabetes. Semaglutide works by mimicking a natural gut hormone called GLP-1, which slows digestion, reduces appetite, and helps regulate blood sugar.

Semaglutide is also sold under other brand names depending on the approved use: Wegovy for chronic weight management, and Rybelsus as an oral tablet version for diabetes. Across all of these, the active ingredient is the same molecule, just approved for different indications and sometimes different doses.

What Is Retatrutide?

Retatrutide is an investigational drug developed by Eli Lilly, the same company behind tirzepatide (Mounjaro, Zepbound). Unlike semaglutide, which targets only the GLP-1 receptor, retatrutide is designed as a triple hormone receptor agonist, meaning it acts on three separate pathways at once: GLP-1, GIP, and glucagon.

That third target, the glucagon receptor, is the key structural difference. GLP-1 and GIP both work to suppress appetite and improve blood sugar control, while adding a glucagon-receptor effect is thought to increase energy expenditure, meaning the body burns more energy at rest. This is the mechanism researchers believe explains why retatrutide has produced larger average weight loss in trials than drugs that target fewer receptors.

Importantly, retatrutide is not currently approved for any use. It’s still moving through Phase 3 clinical trials.

Mechanism Comparison

FDA Approval Status: The Biggest Difference

This is where the two drugs diverge most sharply, and it’s the single most important thing to understand if you’re trying to compare them.

Ozempic has been FDA-approved and on the market since 2017, with years of real-world prescribing data behind it. Retatrutide has never been approved for any indication. As of mid-2026, Eli Lilly announced positive results from two pivotal Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, and stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Given typical FDA review timelines, that means approval, if it happens, likely wouldn’t arrive before late 2027 or into 2028.

Worth noting: retatrutide’s planned submission is a Biologics License Application rather than a standard New Drug Application, which reflects its classification as a larger, more complex molecule under FDA rules, similar to how several other peptide-based therapies are regulated as biologics rather than conventional drugs.

There’s also a real-world safety concern worth flagging directly. Because retatrutide has generated so much media attention, counterfeit and unauthorized versions are already being sold online, despite the drug never having been approved or made available by prescription. The FDA has specifically warned against this, since anything sold under the name “retatrutide” right now has not gone through any manufacturing oversight or safety review at all.

Weight Loss Results: What the Data Actually Shows

It’s tempting to line up percentages from different trials and declare a winner, but that comes with a real caveat: these results come from separate trials with different populations, not head-to-head comparisons, so treat the comparison as directional rather than exact.

Across its Phase 3 program, retatrutide has consistently shown some of the largest average weight-loss results reported for this drug class so far, including figures that approach outcomes historically associated with bariatric surgery. That said, “largest in trials so far” is not the same as “approved and available,” and trial results don’t always translate identically once a drug reaches a much larger, more varied real-world population.

Side Effects: What’s Known So Far

Ozempic’s side effect profile is well documented after years of real-world use. Common effects include nausea, vomiting, diarrhea, and constipation, along with less common but more serious risks like pancreatitis and gallbladder issues.

Retatrutide’s side effects reported in trials so far appear broadly similar in category, mainly gastrointestinal issues like nausea and diarrhea, consistent with other drugs in this class. However, it’s important to be direct about a real limitation here: because retatrutide hasn’t completed the approval process or reached a broad patient population, its full safety profile isn’t established the way Ozempic’s is. Some of retatrutide’s dedicated safety studies, including research into long-term heart, liver, and kidney effects, aren’t expected to report results until 2029.

Retatrutide Is Also Being Studied Beyond Weight Loss

One more distinction worth knowing: Eli Lilly is studying retatrutide for several conditions beyond general weight management, including knee osteoarthritis pain and obstructive sleep apnea, in addition to type 2 diabetes. Ozempic’s approved use, by contrast, is specifically type 2 diabetes, with weight management covered separately under the Wegovy brand name using the same active ingredient.

Why People Confuse the Two (Retatrutide vs Ozempic Confusions)

The confusion is understandable. Both drugs are injectable, both are dosed weekly. Reta and Ozempic are discussed constantly in the same wave of news coverage about the GLP-1 drug boom. They come from major pharmaceutical companies racing to lead this specific market. It’s easy for headlines to blur together, especially when articles compare percentages and mechanisms without clearly stating which drugs are actually approved and which are still investigational.

The clearest way to keep them straight: Ozempic is a real, prescribable, FDA-approved medication today. Retatrutide is a promising but still-unapproved drug that, as of now, no one can legally obtain through a doctor’s prescription.

Frequently Asked Questions

Can I get a prescription for retatrutide right now?

No. Retatrutide is not FDA-approved and is not available through a legitimate prescription outside of clinical trial participation.

Is retatrutide stronger than Ozempic?

Trial data so far suggests retatrutide produces larger average weight loss than semaglutide, but this comes from separate trials rather than a direct head-to-head comparison, so it’s not a confirmed, apples-to-apples result.

When will retatrutide be available?

Eli Lilly plans to submit for FDA approval in early 2027. Given typical review timelines, availability wouldn’t realistically happen before late 2027 or 2028, and that assumes the FDA approves it.

Is it safe to buy retatrutide online right now?

No. Since retatrutide isn’t approved, anything sold under that name currently comes with no manufacturing oversight or safety verification. The FDA has specifically warned consumers about counterfeit versions already circulating.

Does retatrutide work the same way as Ozempic?

No. Ozempic targets only the GLP-1 receptor, while retatrutide targets GLP-1, GIP, and glucagon receptors together, which is the mechanism believed to drive its larger reported weight-loss results.